Literature DB >> 9816199

Synergistic interaction between cisplatin and gemcitabine in vitro.

A M Bergman1, V W Ruiz van Haperen, G Veerman, C M Kuiper, G J Peters.   

Abstract

2',2'-Difluorodeoxycytidine (dFdC; gemcitabine) is a new antineoplastic agent that is active against ovarian carcinoma, non-small-cell lung carcinoma, and head and neck squamous cell carcinoma. cis-diamminedichloroplatinum (CDDP; cisplatin) is used commonly for the treatment of these tumors. Because the two drugs have mechanisms of action that might be complementary, we investigated a possible synergism between dFdC and CDDP on growth inhibition. The combination was tested in the human ovarian carcinoma cell line A2780, its CDDP-resistant variant ADDP and its dFdC-resistant variant AG6000, the human head and neck squamous cell carcinoma cell line UMSCC-22B, and the murine colon carcinoma cell line C26-10. The cells were exposed to dFdC and CDDP as single agents and to combinations in a molar ratio of 1:500 for 1, 4, 24, and 72 h with a total culture time of 72 h. Synergy was evaluated using the multiple drug effect analysis. In A2780 and ADDP cells, simultaneous exposure to the drugs for 24 and 72 h resulted in synergism, but shorter exposure times were antagonistic. No synergism was found in the UMSCC-22B and C26-10 cell lines at prolonged simultaneous exposure. However, a preincubation with CDDP for 4 h followed by a dFdC incubation for 1, 4, 24, and 72 h was synergistic in all cell lines except C26-10 cells. A 4-h preincubation with dFdC followed by an incubation with the combination for 20 and 68 h was synergistic in all cell lines. Initial studies of the mechanism of interaction concentrated on the effect of CDDP on dFdCTP accumulation and DNA strand break formation. In all cell lines, CDDP failed to increase dFdCTP accumulation at 4- or 24-h exposure to dFdC; in two cell lines, CDDP even tended to decrease dFdCTP accumulation. Neither dFdC nor CDDP caused more than 25% double strand break formation, whereas in the combination, CDDP even tended to decrease this type of DNA damage. The synergistic interaction between the two drugs is possibly the result of dFdC incorporation into DNA and/or CDDP-DNA adduct formation, which may be affected by each other.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816199

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  67 in total

Review 1.  Current and future strategies for combined-modality therapy in pancreatic cancer.

Authors:  Andrew H Ko; Margaret A Tempero
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

Review 2.  Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.

Authors:  S Noble; K L Goa
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 3.  Novel therapies in peripheral T-cell lymphomas.

Authors:  Hilary M O'Leary; Kerry J Savage
Journal:  Curr Hematol Malig Rep       Date:  2008-10       Impact factor: 3.952

4.  Chemotherapy: Gemcitabine alone or plus cisplatin for biliary tract cancer?

Authors:  Werner Scheithauer
Journal:  Nat Rev Clin Oncol       Date:  2010-10       Impact factor: 66.675

Review 5.  Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?

Authors:  Ramya Thota; Anirban Maitra; Jordan D Berlin
Journal:  Pancreas       Date:  2017-02       Impact factor: 3.327

6.  Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas.

Authors:  Aaron T Wild; Avani S Dholakia; Katherine Y Fan; Rachit Kumar; Shalini Moningi; Lauren M Rosati; Daniel A Laheru; Lei Zheng; Ana De Jesus-Acosta; Susannah G Ellsworth; Amy Hacker-Prietz; Khinh R Voong; Phuoc T Tran; Ralph H Hruban; Timothy M Pawlik; Christopher L Wolfgang; Joseph M Herman
Journal:  J Gastrointest Oncol       Date:  2015-04

Review 7.  Novel therapies in peripheral T-cell lymphomas.

Authors:  Hilary M O'Leary; Kerry J Savage
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

8.  Activation of c-Jun NH2-terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells.

Authors:  Fuminori Teraishi; Lidong Zhang; Wei Guo; Fengqin Dong; John J Davis; Anning Lin; Bingliang Fang
Journal:  FEBS Lett       Date:  2005-11-14       Impact factor: 4.124

9.  Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer.

Authors:  Ralf Wilkowski; Martin Thoma; Rolf Schauer; Andreas Wagner; Volker Heinemann
Journal:  World J Surg       Date:  2004-09-29       Impact factor: 3.352

10.  Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group.

Authors:  I Ray-Coquard; B Weber; J Cretin; Z Haddad-Guichard; E Lévy; A C Hardy-Bessard; M C Gouttebel; J-F Geay; A Aleba; H Orfeuvre; C Agostini; J Provencal; J M Ferrero; D Fric; N Dohollou; D Paraiso; J Salvat; E Pujade-Lauraine
Journal:  Br J Cancer       Date:  2009-02-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.